WA-T-MOBILE
Today, T-Mobile (NASDAQ: TMUS) announced that Battle Motors has selected the Un-carrier as the preferred provider of IoT connectivity and management for thousands of new Battle Motors battery electric trucks rolling off the Ohio-based production line. And these trucks are getting smarter, thanks to Battle Motors' all new factory installed RevolutionOS™ EV software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005589/en/
Like consumer automotive, the commercial truck industry is moving swiftly to embrace EV technology — and Battle Motors is no exception. Their RevolutionOS™, powered by T-Mobile's nationwide network, delivers actionable data and information to drivers and fleet managers that they can use to enhance efficiency, safety, and security. As part of this long-term agreement, T-Mobile for Business will deliver 4G LTE connectivity to Battle Motors trucks for near real-time sharing of battery range and usage information, historic and near real-time location and trip data, timely preventative maintenance warnings, over-the-air software, and firmware updates — as well as the truck's full bill of materials, such as VIN-specific information, parts, and manuals.
Every new Battle Motors class seven and class eight "heavy-duty" EV truck — like the ones that haul garbage, dirt, and freight — will come with a factory installed, ruggedized digital instrument cluster that runs RevolutionOS™. And thanks to the power and reliability of T-Mobile's nationwide network, Battle Motors’ RevolutionOS™ will let customers view and update critical information directly from the truck, or remotely from a desktop computer or mobile device, just by scanning a QR code!
Additionally, T-Mobile Control Center will give Battle Motors the ability to view and manage the connectivity of their trucks. With the automation and provisioning capabilities of T-Mobile’s IoT platform, Battle Motors can easily accelerate deployment of their growing line of trucks. Battle Motors will have near real-time visibility to all their commercial trucks with the ability to monitor network conditions and device behavior with T-Mobile Control Center.
In the near future, Battle Motors expects to leverage the Un-carrier's 5G network to meet industrial-sized challenges for years to come as their trucks’ capabilities advance and the demands on connectivity increase. T-Mobile is poised to push IoT to its full potential and catapult adoption — paving the way for new electric vehicle applications that rely on low-latency, high-speed data, and real-time location and proximity-based services.
“Our primary focus has been on driving technology and innovation that gives our customers value and peace-of-mind when it comes to maintenance, efficiency, safety and compliance,” says Battle Motors CSO, Paul Marsolan. “Together with T-Mobile, we’re able to merge analytics and operations to put rich, real-time decision-making data to work for our customers.”
“While we continue to grow our business market share, it energizes us to work with forward thinking companies that demonstrate leadership in areas like sustainable commercial transportation,” said Callie Field, President, T-Mobile Business Group. “Reliable connectivity, management and support is central to Battle Motors’ mission, and we’re honored that they entrusted their trucks and their customers to T-Mobile for Business.”
For more information about IoT from T-Mobile for Business, visit www.t-mobile.com/business/solutions/iot .
To find out more about Battle Motors, go to www.battlemotors.com .
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com .
About Battle Motors
Battle Motors, a leader in the development of electric vehicle (EV) technology, acquired commercial vehicle Original Equipment Manufacturer (OEM), Crane Carrier Company, LLC (CCC) in 2021. Battle Motors is the leader in the vocational truck industry, providing work-ready diesel, clean natural gas (CNG), and now EV chassis designed and manufactured in North America for the refuse and recycling markets. Battle Motor’s durable, dependable trucks are built to excel in a multitude of applications that now include middle-mile and last-mile delivery. CCC has been manufacturing commercial vehicles for 75 years and is based in New Philadelphia, Ohio. For more information please visit: https://www.battlemotors.com and follow us @BattleMotors
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005589/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release
Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e
Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release
Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has
Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release
Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa
Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release
News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra
Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom